Anavex Life Sciences Corp. is engaged in developing small molecule treatments aimed at addressing central nervous system (CNS) diseases, including Alzheimer's and Parkinson's diseases. Their approach focuses on targeting the Sigma-1 receptor and utilizing their SIGMACEPTOR™ platform.

Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

COM:ANAVEX

Anavex Life Sciences Corp.

Last Close

9.02

22/11 21:00

Market Cap

731.79M

Beta: -

Volume Today

1.95M

Avg: -

Analysis Not Available